Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 10, 2010 Brian Orelli	When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.
The Motley Fool June 16, 2011 Brian Orelli	Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.
The Motley Fool June 21, 2011 Alexander Crawford	Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list?
The Motley Fool July 11, 2008 Brian Orelli	Pfizer Looking at a Level Playing Field An advisory panel says that epilepsy drugs don't need a black-box warning, news that is positive for drug companies -- that is, those other than Pfizer.
The Motley Fool June 29, 2009 Brian Orelli	REMS: Not Just for Sleeping Anymore Risk Evaluation and Mitigation Strategies is saving drugmakers from going into a deep sleep while they wait for Food and Drug Administration approval of their drugs.
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool March 12, 2009 Robert Steyer	A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
The Motley Fool September 23, 2010 Brian Orelli	Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease.
Pharmaceutical Executive July 1, 2009 Jill Wechsler	Safety and Security As FDA looks to balance risks and benefits, more regulations are on the horizon.
Fast Company November 2004 Scott Kirsner	A Slow, Patient Pace A follow-up to a recent story on a pacemaker that helps patients with epilepsy and seeks additional approval for patients who suffer from severe, drug-resistant depression -- including comments from the parents of a six-year-old epileptic who is using the device.
American Family Physician July 1, 2001 Selim R. Benbadis	Advances in the Treatment of Epilepsy Significant advances have been made in the diagnosis and treatment of epilepsy over the past decade...
Chemistry World August 26, 2015 Sarah Houlton	Female sexual desire drug approved Almost five years after Boehringer Ingelheim stopped development on the female hypoactive sexual desire disorder treatment flibanserin, it has been approved by the US Food and Drug Administration.
American Family Physician July 1, 2001	What Should I Know About Seizures and Epilepsy? What is a seizure, and what is epilepsy?... What causes epilepsy?... Who gets epilepsy?... Are all seizures the same?... How does the doctor find out I have epilepsy?...
Managed Care March 2008 Martin Sipkoff	The Epilepsy Battle in the War Between Brands and Generics Brand-name manufacturers and many neurologists see danger in generic substitution, but the FDA insists that the practice is safe
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 18, 2010 Brian Orelli	More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide.
BusinessWeek October 1, 2009	Stalking the Future J&J lost patent protection on epilepsy and schizophrenia drugs worth $7 billion last year. These new drugs, if cleared by the FDA, could help offset the damage.
American Family Physician January 15, 2003 Velez & Selwa	Seizure Disorders in the Elderly Seizure disorders become increasingly common after the age of 60 years and can have a significant impact on functional status. The goal of antiepileptic drug therapy is to control seizures but preserve quality of life.
Pharmaceutical Executive July 30, 2007 Louis A. Morris	Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages.
American Family Physician September 1, 2005 Alsaadi & Marquez	Psychogenic Nonepileptic Seizures Often misdiagnosed and treated for epilepsy, these seizures are unique in that they do not have a neurologic origin.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool August 19, 2011 Cindy Johnson	12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them?
The Motley Fool September 8, 2008 Rich Duprey	The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information.
American Family Physician September 1, 2000 Gary N. McAbee & James E. Wark	A Practical Approach to Uncomplicated Seizures in Children Uncomplicated seizures and epilepsy are common in infants and children. Not all uncomplicated childhood seizures require neuroimaging or treatment...
IEEE Spectrum May 2005 Samuel K. Moore	Zapping Away The Blues Cyberonics Inc. plans to introduce the first implanted device that can treat a psychiatric illness.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
Nurse Practitioner February 2012 Jennifer M. Belavic	Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice
Pharmaceutical Executive August 1, 2012 William Looney	The Phrase that Plays The FDA is creatively applying regulatory fiat to force fundamental changes in company culture.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
IEEE Spectrum June 2009 Virginia Hughes	A New Approach to Predicting Epileptic Seizures Torrents of data produced by implanted microelectrodes could finally yield a prediction system
Nursing September 1, 2007 Mary Unruh Fagley	Taking Charge of Seizure Activity Learn what happens during a seizure when the brain's electric signals go awry and how you can help someone plagued by the disturbing effects.
Pharmaceutical Executive November 1, 2005 Sara Calabro	Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles.
Chemistry World March 25, 2015 Phillip Broadwith	Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals.
Reactive Reports July 2004 David Bradley	Breaking the Cycle of Epilepsy in Women Researchers have made an important discovery about a form of epilepsy that affects women most severely during menstruation. The findings could lead to a new treatment based on manipulating levels of the hormone progesterone.
The Motley Fool March 30, 2011 Brian Orelli	Valeant Vultures Will Cephalon manage to rebuff Valeant's advances?
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
American Family Physician October 15, 2002 Martha J. Morrell	Epilepsy in Women Epilepsy in women raises special reproductive and general health concerns. Seizure frequency and severity may change at puberty, over the menstrual cycle, with pregnancy, and at menopause.